ATE280575T1 - Transdermales therapeutisches system zur anwendung von candesartan - Google Patents

Transdermales therapeutisches system zur anwendung von candesartan

Info

Publication number
ATE280575T1
ATE280575T1 AT99922167T AT99922167T ATE280575T1 AT E280575 T1 ATE280575 T1 AT E280575T1 AT 99922167 T AT99922167 T AT 99922167T AT 99922167 T AT99922167 T AT 99922167T AT E280575 T1 ATE280575 T1 AT E280575T1
Authority
AT
Austria
Prior art keywords
candesartan
therapeutic system
transdermal therapeutic
administration
salts
Prior art date
Application number
AT99922167T
Other languages
German (de)
English (en)
Inventor
Thomas Struengmann
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Application granted granted Critical
Publication of ATE280575T1 publication Critical patent/ATE280575T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99922167T 1998-05-06 1999-05-04 Transdermales therapeutisches system zur anwendung von candesartan ATE280575T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19820151A DE19820151A1 (de) 1998-05-06 1998-05-06 Transdermales therapeutisches System zur Anwendung von Candesartan
PCT/EP1999/003029 WO1999056734A2 (de) 1998-05-06 1999-05-04 Transdermales therapeutisches system zur anwendung von candesartan

Publications (1)

Publication Number Publication Date
ATE280575T1 true ATE280575T1 (de) 2004-11-15

Family

ID=7866803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922167T ATE280575T1 (de) 1998-05-06 1999-05-04 Transdermales therapeutisches system zur anwendung von candesartan

Country Status (8)

Country Link
EP (1) EP1085858B1 (enExample)
JP (1) JP4659982B2 (enExample)
AT (1) ATE280575T1 (enExample)
AU (1) AU760550B2 (enExample)
BR (1) BR9910201A (enExample)
CA (1) CA2331414C (enExample)
DE (2) DE19820151A1 (enExample)
WO (1) WO1999056734A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60045211D1 (de) 1999-02-19 2010-12-23 Takeda Pharmaceutical Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii-rezeptorantagonismus aufweisen
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
EP1711168A2 (en) * 2004-01-23 2006-10-18 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
JP5308788B2 (ja) * 2008-11-27 2013-10-09 興和株式会社 貼付剤
CA2766120C (en) * 2009-07-07 2018-08-14 Convatec Technologies Inc. Amphiphilic silicone copolymers for pressure sensitive adhesive applications
CN104356116A (zh) * 2014-10-17 2015-02-18 北京理工大学 坎地沙坦有机胺盐及氨盐的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (enExample) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE58906975D1 (de) * 1988-08-02 1994-03-24 Ciba Geigy Mehrschichtiges Pflaster.
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2256135B (en) * 1991-05-31 1995-01-18 Orion Yhtymae Oy Transdermal administration of 4-substituted imidazoles
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
DE4341444C2 (de) * 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung
DE19512181C2 (de) * 1995-03-31 2003-11-06 Hexal Pharma Gmbh Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途

Also Published As

Publication number Publication date
EP1085858B1 (de) 2004-10-27
WO1999056734A3 (de) 2000-01-27
WO1999056734A2 (de) 1999-11-11
EP1085858A2 (de) 2001-03-28
DE59910944D1 (de) 2004-12-02
DE19820151A1 (de) 1999-11-11
CA2331414C (en) 2008-09-16
JP4659982B2 (ja) 2011-03-30
JP2002513753A (ja) 2002-05-14
AU3931199A (en) 1999-11-23
AU760550B2 (en) 2003-05-15
BR9910201A (pt) 2001-01-09
CA2331414A1 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
DE69807634D1 (de) Medizinische einrichtung zur verabreichung von therapeutischen wirkstoffen
HUP9901991A2 (hu) Transzdermális eszköz flurbiprofén átadására
SE8703034D0 (sv) Oralt terapeutiskt system med systemisk verkan
BG103552A (bg) Терапевтични средства
DK0949925T3 (da) Flad lægemiddelform til anbringelse i mundhulen med frigivelse der af buprenorphin eller et farmakologisk sammenligneligt stof, samt fremgangsmåde til fremstilling deraf
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
NO952906D0 (no) Farmasöytisk formulering for behandling av nikotinavhengighet
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
HUP0000963A2 (hu) A levobupivakain gyermeksebészeti alkalmazása
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
DK1069902T3 (da) Anvendelse af phospholipider til fremstilling af et lægemiddel til forebyggelse af adhæsioner
ATE280575T1 (de) Transdermales therapeutisches system zur anwendung von candesartan
MX9701968A (es) Emplasto de escopolamina.
DE69934689D1 (de) Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen
NO975140D0 (no) Transdermalt terapeutisk system (TTS) for administrasjon av testosteron
ATE238054T1 (de) Pflaster zur transdermalen anwendung von pergolid
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
ATE295157T1 (de) Mittel zur transdermalen verabreichung von arzneistoffen
DE59914183D1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
ES2129563T3 (es) Empleo de una combinacion de un inhibidor de la enzima convertidora de angiotensina y un antagonista del calcio para el tratamiento de una proteinuria.
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
DE60028207D1 (de) Transdermales therapeutisches system zur verabreichung von calciumantagonisten
ATE371446T1 (de) Zusammensetzungen zur verhinderung der adhäsion